{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:30:57Z","timestamp":1793939457401,"version":"4.8.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,3,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this phase 2 study was to evaluate the efficacy and safety of trastuzumab, a humanized monoclonal antibody targeted against the human epidermal growth factor receptor 2 (HER2), for adult patients with relapsed\/refractory HER2-positive B-ALL. Fifteen patients, with a median age of 62 years, received trastuzumab according to the schedule approved for breast cancer patients (ie, 4 mg\/kg intravenous loading dose followed by 2 mg\/kg weekly). The overall response rate was 13% with 2 patients achieving partial response and partial remission cytolytic response, respectively. Two other patients were documented with blast clearance. Only 1 reversible grade 3 cardiac toxic event occurred. This phase 2 study showed that trastuzumab monotherapy can allow for some responses in a very high-risk refractory\/relapsed HER2-positive adult B-ALL population. Combination of trastuzumab with chemotherapy or other therapeutic monoclonal antibodies should be tested in the future. This trial was registered at www.clinicaltrials.gov\/ct as NCT00724360.<\/jats:p>","DOI":"10.1182\/blood-2011-11-390781","type":"journal-article","created":{"date-parts":[[2012,1,21]],"date-time":"2012-01-21T06:01:47Z","timestamp":1327125707000},"page":"2474-2477","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":15,"title":["Trastuzumab for treatment of refractory\/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study"],"prefix":"10.1182","volume":"119","author":[{"given":"Patrice","family":"Chevallier","sequence":"first","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire (CHU) H\u00f4tel Dieu, Universit\u00e9 de Nantes, Centre d'Investigation Clinique en Cancerologie (CI2C) and Inserm U892, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Robillard","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie\/Biologie, CHU H\u00f4tel-Dieu, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aude","family":"Charbonnier","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Institut Paoli-Calmette, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Raffoux","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Assistance Publique\u2013Hopitaux de Paris (AP-HP), H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Maury","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, AP-HP, H\u00f4pital Henri Mondor, Cr\u00e9teil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Carras","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, CHU, H\u00f4pital A. Michallon, Grenoble, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Chabrot","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, CHU, Clermont-Ferrand, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Fohrer","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Centre Hospitalier Regional Universitaire, H\u00f4pital Hautepierre, Strasbourg, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bernard","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, CHU, Rennes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Sebastien","family":"Blade","sequence":"additional","affiliation":[{"name":"Service de M\u00e9decine Interne-Oncologie, HIA Sainte-Anne, Toulon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Etienne","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Institut Paoli-Calmette, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascaline","family":"Talmant","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire (CHU) H\u00f4tel Dieu, Universit\u00e9 de Nantes, Centre d'Investigation Clinique en Cancerologie (CI2C) and Inserm U892, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Delaunay","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire (CHU) H\u00f4tel Dieu, Universit\u00e9 de Nantes, Centre d'Investigation Clinique en Cancerologie (CI2C) and Inserm U892, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire (CHU) H\u00f4tel Dieu, Universit\u00e9 de Nantes, Centre d'Investigation Clinique en Cancerologie (CI2C) and Inserm U892, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie Clinique, Centre Hospitalier Universitaire (CHU) H\u00f4tel Dieu, Universit\u00e9 de Nantes, Centre d'Investigation Clinique en Cancerologie (CI2C) and Inserm U892, Nantes, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Bene","sequence":"additional","affiliation":[{"name":"Service d'Immunologie, CHU et Universit\u00e9 de Nancy, Nancy, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Ifrah","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, CHU, Angers, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herve","family":"Dombret","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie, Assistance Publique\u2013Hopitaux de Paris (AP-HP), H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"18","key":"2019111807452715800_B1","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","article-title":"Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.","volume":"29","author":"Topp","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111807452715800_B2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/leu.2010.239","article-title":"Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia.","volume":"25","author":"Handgretinger","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"2019111807452715800_B3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/leu.2008.303","article-title":"Simultaneous study of five candidate target antigens (CD20, CD22, CD33, CD52, HER2) for antibody-based immunotherapy in B-ALL: a monocentric study of 44 cases.","volume":"23","author":"Chevallier","year":"2009","journal-title":"Leukemia"},{"issue":"7","key":"2019111807452715800_B4","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with Hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leucemia.","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"issue":"24","key":"2019111807452715800_B5","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.","volume":"28","author":"Thomas","year":"2010","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111807452715800_B6","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111807452715800_B7","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12185-008-0123-2","article-title":"Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukaemia patient harbouring CD33 expression.","volume":"88","author":"Chevallier","year":"2008","journal-title":"Int J Hematol"},{"issue":"9","key":"2019111807452715800_B8","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/sj.leu.2403422","article-title":"Remission of adult acute lymphocytic leukaemia with alemtuzumab.","volume":"18","author":"Laporte","year":"2004","journal-title":"Leukemia"},{"key":"2019111807452715800_B9","article-title":"Activity and resistance of trastuzumab according to different clinical settings [published online ahead of print, July 2, 2011].","author":"Tagliabue","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"2019111807452715800_B10","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized antiHER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111807452715800_B11","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111807452715800_B12","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","article-title":"Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.","volume":"23","author":"Marty","year":"2005","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111807452715800_B13","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","article-title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.","volume":"353","author":"Piccart-Gebhart","year":"2005","journal-title":"N Engl J Med"},{"issue":"9555","key":"2019111807452715800_B14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)60028-2","article-title":"2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial.","volume":"369","author":"Smith","year":"2007","journal-title":"Lancet"},{"issue":"9742","key":"2019111807452715800_B15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"issue":"11","key":"2019111807452715800_B16","first-page":"1399","article-title":"Overexpression of Her2\/neu is observed in one third of adult acute lymphoblastic leukaemia patients and is associated with chemoresistance in these patients.","volume":"89","author":"Chevallier","year":"2004","journal-title":"Haematologica"},{"issue":"7","key":"2019111807452715800_B17","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O","article-title":"Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.","volume":"86","author":"Thomas","year":"1999","journal-title":"Cancer"},{"issue":"3","key":"2019111807452715800_B18","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL): an MRC UKALL12\/ECOG 2993 study.","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2019111807452715800_B19","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/sj.leu.2404824","article-title":"Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial.","volume":"21","author":"Tavernier","year":"2007","journal-title":"Leukemia"},{"issue":"4","key":"2019111807452715800_B20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3324\/haematol.2009.014274","article-title":"Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA study Group.","volume":"95","author":"Oriol","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"2019111807452715800_B21","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2.","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111807452715800_B22","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23824","article-title":"Early treatment of high-risk chronic lymphoblastic leukaemia with alemtuzumab and rituximab.","volume":"113","author":"Zent","year":"2008","journal-title":"Cancer"},{"issue":"26","key":"2019111807452715800_B23","doi-asserted-by":"crossref","first-page":"5930","DOI":"10.1182\/blood-2010-01-262006","article-title":"A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.","volume":"116","author":"Nijmeijer","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2019111807452715800_B24","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111807452715800_B25","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PAP.0b013e3182026d72","article-title":"HER2 testing in gastric cancer.","volume":"18","author":"Albarello","year":"2011","journal-title":"Adv Anat Pathol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/11\/2474\/1350069\/zh801112002474.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/11\/2474\/1350069\/zh801112002474.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:57:48Z","timestamp":1574081868000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/11\/2474\/29591\/Trastuzumab-for-treatment-of-refractoryrelapsed"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,15]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,3,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-11-390781","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,15]]}}}